Paul F. Schellhammer
#133,761
Most Influential Person Now
Paul F. Schellhammer's AcademicInfluence.com Rankings
Paul F. Schellhammerphilosophy Degrees
Philosophy
#6650
World Rank
#9718
Historical Rank
Logic
#3783
World Rank
#4992
Historical Rank
Download Badge
Philosophy
Why Is Paul F. Schellhammer Influential?
(Suggest an Edit or Addition)Paul F. Schellhammer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (2010) (4808)
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. (2006) (2358)
- Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. (2006) (1082)
- Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. (1997) (1079)
- Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. (2002) (958)
- Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. (2007) (815)
- Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer (2009) (800)
- Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. (1996) (592)
- Intermittent versus continuous androgen deprivation in prostate cancer. (2013) (471)
- Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. (1995) (470)
- Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. (2002) (456)
- Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. (2001) (414)
- Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. (2014) (377)
- Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. (1999) (334)
- Intermittent androgen suppression for rising PSA level after radiotherapy. (2012) (326)
- Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. (2002) (297)
- Results of radical prostatectomy in men with clinically localized prostate cancer. (1996) (237)
- Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. (2013) (224)
- Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. (2000) (224)
- Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. (1995) (199)
- Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. (2013) (189)
- Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. (2002) (185)
- Improved detection of recurrent bladder cancer using the Bard BTA stat Test. (1998) (184)
- Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. (2001) (173)
- Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. (1997) (173)
- Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. (1999) (173)
- Quality of life after treatment for localized prostate cancer: differences based on treatment modality. (2001) (162)
- Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. (1995) (162)
- Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. (1977) (145)
- Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. (1997) (139)
- Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. (1995) (129)
- Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer (2011) (128)
- Laparoscopic radical prostatectomy: decreasing the learning curve using a mentor initiated approach. (2003) (126)
- Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. (2001) (124)
- Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. (1997) (120)
- Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. (2009) (119)
- Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy (2013) (117)
- Spontaneous regression of metastatic renal cell carcinoma. (1982) (110)
- Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. (1995) (103)
- Radical prostatectomy. Patterns of local failure and survival in 67 patients. (1988) (102)
- A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. (1995) (102)
- Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. (1987) (102)
- Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. (1993) (99)
- The significance of post-irradiation prostate biopsy with long-term follow-up. (1992) (99)
- Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. (2001) (96)
- Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. (1997) (96)
- I–125 interstitial implantation for prostate cancer. What have we learned 10 years later? (1989) (95)
- Data Reduction Using a Discrete Wavelet Transform in Discriminant Analysis of Very High Dimensionality Data (2003) (92)
- Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. (2001) (91)
- Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. (2010) (90)
- Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? (1999) (90)
- Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. (2002) (90)
- Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens (2018) (89)
- A re‐assessment of the role of combined androgen blockade for advanced prostate cancer (2004) (88)
- Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder. (1986) (87)
- Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. (2009) (86)
- The adrenal gland and renal cell carcinoma: is ipsilateral adrenalectomy a necessary component of radical nephrectomy? (1986) (83)
- Prostate biopsy after definitive treatment by interstitial 125iodine implant or external beam radiation therapy. (1987) (83)
- Conservative surgical therapy for penile and urethral carcinoma. (1999) (78)
- Pulmonary metastases from prostate cancer (1995) (74)
- Ex situ study of the effectiveness of enucleation in patients with renal cell carcinoma. (1988) (73)
- Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. (2011) (69)
- Four cases of metastases to the penis and a review of the literature. (1984) (68)
- Monoclonal antibodies to human prostate and bladder tumor-associated antigens. (1982) (65)
- Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin. (1988) (65)
- Histochemical Studies of the Myocardium and Conduction System in Acquired Iron‐Storage Disease (1967) (64)
- Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer. (1992) (63)
- Effects of the calcium influx inhibitor carboxyamido‐triazole on the proliferation and invasiveness of human prostate tumor cell lines (1996) (63)
- Treatment options for localized prostate cancer. (2011) (62)
- Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma. (2000) (61)
- Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. (1999) (61)
- Five-alpha-reductase Inhibitors for prostate cancer prevention. (2008) (61)
- Treatment of clinical local failure after radiation therapy for prostate carcinoma. (1993) (60)
- Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. (2006) (60)
- An evaluation of bicalutamide in the treatment of prostate cancer (2002) (60)
- Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry (2020) (59)
- Analysis of prostatic tumor cultures using fluorescence in-situ hybridization (FISH). (1992) (59)
- Calcium signaling in prostate cancer cells: Evidence for multiple receptors and enhanced sensitivity to bombesin/GRP (1997) (59)
- Characteristics of spinal cord compression in adenocarcinoma of prostate. (1986) (57)
- Pelvic complications after definitive treatment of prostate cancer by interstitial or external beam radiation. (1983) (56)
- Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. (2012) (56)
- Cytogenetic evaluation of 20 cultured primary prostatic tumors. (1991) (55)
- Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. (2007) (54)
- Assessment of endpoints for clinical trials for localized prostate cancer. (1997) (54)
- The effect of prior transurethral resection of the prostate on post radiation urethral strictures and bladder neck contractures. (1986) (53)
- A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013). (2011) (53)
- Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response. (1997) (53)
- Zoladex versus orchiectomy in treatmentof advanced prostate cancer: a randomized trial (1991) (52)
- Malignant epithelial tumors (2004) (51)
- Guideline for the Management of Nonmuscle Invasive Bladder Cancer : ( Stages Ta , T 1 , and Tis ) : 2007 Update Bladder Cancer (2014) (50)
- Major rectal complications following interstitial implantation of 125iodine for carcinoma of the prostate. (1985) (50)
- Premalignant lesions and nonsquamous malignancy of the penis and carcinoma of the scrotum. (1992) (50)
- Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. (2009) (50)
- Intravesical bacillus Calmette-Guerin for the treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder. (1995) (49)
- The use of microsurgical denervation of the spermatic cord for orchialgia. (1978) (49)
- External sphincterotomy: an evaluation of 150 patients with neurogenic bladder. (1973) (49)
- Half-body irradiation for treatment of widely metastatic adenocarcinoma of the prostate. (1989) (48)
- 5‐α‐Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review (2010) (48)
- Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma (1989) (47)
- Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer. (2005) (47)
- Repair of obliterative vesicourethral stricture after radical prostatectomy: a technique for preservation of continence. (1995) (45)
- Comparison of goserelin and leuprolide in combined androgen blockade therapy. (1998) (45)
- Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. (1996) (45)
- Potential benefit of improved local tumor control in patients with prostate carcinoma (1995) (45)
- Local failure after definitive therapy for prostatic cancer. (1987) (44)
- Overexpression of α-defensin is associated with bladder cancer invasiveness (2006) (44)
- Cytogenetic analysis of four primary prostatic cultures. (1989) (43)
- Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. (1996) (43)
- Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. (2000) (42)
- Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up. (2001) (42)
- Histological characteristics of prostatic biopsies after 125iodine implantation. (1980) (42)
- Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen (1993) (41)
- Intravesical dimethyl sulfoxide for primary amyloidosis of the bladder. (1998) (40)
- Morbidity and mortality of local failure after definitive therapy for prostate cancer. (1989) (40)
- Suprarenal Greenfield filter placement to prevent pulmonary embolus in patients with vena caval tumor thrombi. (1992) (40)
- Immunohistochemical localization of prostate carcinoma-associated antigens. (1983) (40)
- Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. (1999) (39)
- Reevaluation of prostate biopsy after definitive radiation therapy. (1993) (39)
- Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. (1996) (38)
- Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas. (1991) (38)
- Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias. (2003) (37)
- Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG. (1993) (36)
- Carcinoma of the prostate: race as a prognostic indicator in definitive radiation therapy. (1995) (36)
- Voiding impairment after prostate biopsy: does tamsulosin treatment before biopsy decrease this morbidity? (2003) (36)
- Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. (2007) (36)
- Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: Efficacy of flt3 ligand immunotherapy (2003) (35)
- Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer (HRPC) (2005) (35)
- A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone–Releasing hormone analogue therapy, in patients with advanced prostate carcinoma: Analysis of time to progression (1996) (35)
- Human prostate tissue antigens defined by murine monoclonal antibodies. (1986) (35)
- An evaluation of bicalutamide in the treatment of prostate cancer. (2004) (35)
- Combined androgen blockade: the case for bicalutamide. (2005) (35)
- Patients’ Survival Expectations before Localized Prostate Cancer Treatment by Treatment Status (2009) (34)
- Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. (1993) (34)
- Management of bleeding renal angiomyolipomas by transcatheter embolization following CT diagnosis (1984) (34)
- The pursuit of prostate cancer in patients with a rising prostate-specific antigen and multiple negative transrectal ultrasound-guided prostate biopsies. (2002) (32)
- Müllerian duct cysts: conservative management. (1987) (31)
- Overexpression of alpha-defensin is associated with bladder cancer invasiveness. (2006) (31)
- Prostatic carcinoma with cutaneous metastases. (1973) (31)
- Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction. (1998) (31)
- Protein Profiling in Urine for the Diagnosis of Bladder Cancer (2004) (29)
- Renal metastases from carcinoma of the lung. (1986) (29)
- A mode of treatment for incarceration of the penis. (1973) (29)
- Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate. (1991) (28)
- Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer (2005) (28)
- Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary. (2009) (27)
- Combined androgen blockade for the treatment of metastatic cancer of the prostate. (1996) (27)
- Pelvic complications after interstitial and external beam irradiation of urologic and gynecologic malignancy (1986) (27)
- A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. (1996) (26)
- Sural nerve graft during laparoscopic radical prostatectomy. Initial experience. (2002) (25)
- Flow cytometric study comparing paired bladder washing and voided urine for bladder cancer detection. (1989) (25)
- Malignant pericardial effusion as initial solitary site of metastasis from transitional cell carcinoma of the bladder. (1995) (25)
- Self-rated health as a tool for estimating health-adjusted life expectancy among patients newly diagnosed with localized prostate cancer: a preliminary study (2011) (24)
- 125Iodine implantation for carcinoma of the prostate: 5-year survival free of disease and incidence of local failure. (1985) (24)
- Local failure and related complications after definitive treatment of carcinoma of the prostate by irradiation or surgery. (1990) (24)
- PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it? (1998) (24)
- Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. (1996) (24)
- Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. (1995) (23)
- Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review. (1987) (23)
- Mortality associated with feeding catheter jejunostomy after radical cystectomy. (1987) (22)
- Protein profiling of urine in the diagnosis of bladder cancer (2005) (22)
- Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer (2011) (22)
- Malignant epithelial tumours (2006) (22)
- Prostate Tumor Microenvironment Alters Immune Cells and Prevents Long-Term Survival in an Orthotopic Mouse Model Following flt3-Ligand/CD40-Ligand Immunotherapy (2004) (22)
- A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. (1996) (22)
- Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer (2003) (21)
- Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues (1999) (21)
- Bilateral testicular rupture: report of a case with an unusual presentation. (1978) (21)
- Fulminant hepatic failure associated with bicalutamide. (1997) (21)
- High-Grade Prostate Cancer and the Prostate Cancer Prevention Trial (2008) (21)
- Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group. (1991) (21)
- Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir. (1997) (21)
- Prognostic significance of post-irradiation prostate biopsies. (1993) (20)
- The role of routine followup bone scans after definitive therapy of localized prostatic cancer. (1982) (19)
- Squamous cell carcinoma of bladder after successful intravesical therapy with Bacillus Calmette-Guérin. (1989) (18)
- External sphincterotomy: rational for the procedure and experiences with 150 patients (1974) (18)
- Prostatorectal fistula 14 years following brachytherapy for prostate cancer. (2001) (18)
- Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present. (2000) (18)
- AUA/Optimal Techniques of Prostate Biopsy and Specimen Handling (2013) (17)
- Periprostatic Lidocaine Infiltration and/or Synthetic Opioid (Meperidine or Tramadol) Administration Have No Analgesic Benefit during Prostate Biopsy (2004) (17)
- 5-a-Reductase inhibitors for prostate cancer chemoprevention: An updated Cochrane systematic review (BJU International (2010) 106:10 (1444-1451)) (2011) (17)
- Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. (2012) (17)
- Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer. (1994) (17)
- Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC) (2007) (16)
- The durability of external beam radiation therapy for prostate cancer: can it be identified? (1999) (16)
- Laparoscopic radical prostatectomy: evaluation of specimen pathologic features to critically assess and modify surgical technique. (2005) (16)
- Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? (2000) (15)
- Steroid therapy for ureteral obstruction after aortoiliac graft surgery. (1981) (15)
- The clinical and economic implications of specimen provenance complications in diagnostic prostate biopsies. (2015) (15)
- Bilateral testicular lymphoma treated with chemotherapy and radiation without orchiectomy: complete response relapsed at 52 months in the vitreous humor. (2001) (15)
- Transitional cell carcinoma and renal cell adenocarcinoma in single kidney. (1975) (15)
- Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy. (2000) (15)
- Urologic aspects of pancreatic adenocarcinoma. (1981) (15)
- Bropirimine immunotherapy of upper urinary tract carcinoma in situ. (1996) (14)
- The treatment of choice for localized poorly differentiated adenocarcinoma of the prostate (1985) (14)
- Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancer (2010) (14)
- Paraganglioma of urinary bladder in patient with neurofibromatosis. (1986) (14)
- Hemibody irradiation in advanced prostatic carcinoma. (1991) (14)
- Isolation of a soluble tumor-associated antigen from human renal cell carcinoma by gradient acrylamide gel electrophoresis. (1977) (14)
- [Laparoscopic radical cystectomy with intracorporeal creation of a continent urinary diversion. Future or present?]. (2002) (14)
- Estrogen receptor activity in a case of Hodgkin's disease. (1981) (14)
- Local failure after definitive radiation or surgical therapy for carcinoma of the prostate and options for prevention and therapy. (1991) (14)
- Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. (2013) (13)
- Percent free prostate-specific antigen values in men with recurrent prostate cancer after radical prostatectomy. (1998) (13)
- Re: Intravesical bacillus Calmette-Guerin therapy and associated granulomatous renal masses. (1987) (13)
- The effect of TURP on prognosis in prostatic carcinoma. (1986) (13)
- Transitional cell carcinoma: cause of refractory cancer of prostate. (1979) (13)
- An update on bicalutamide in the treatment of prostate cancer. (1999) (13)
- The Prognostic Significance of S–Phase Analysis in Stage Ta/T1 Bladder Cancer (2000) (12)
- Deoxyribonucleic acid cytometric analysis of prostate core biopsy specimens: relationship to serum prostate specific antigen and prostatic acid phosphatase, clinical stage and histopathology. (1993) (12)
- Relative potency of bicalutamide (Casodex) and flutamide (Eulexin) (1999) (12)
- Laparoscopic radical prostatectomy: is intact organ removal attainable? Study of margin status. (2004) (12)
- Massive intrascrotal fibrolipoma. (1983) (12)
- Epithelioid sarcoma of the penis. (1988) (12)
- Principles, Hazards, and Precautions (1974) (12)
- Prostate gland and extra-capsular tissue 3D reconstruction and measurement (2003) (11)
- Comparison of transrectal fine-needle aspiration cytology and core needle biopsy in diagnosis of prostate cancer. (1990) (11)
- Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. (2005) (11)
- 605: Androgen Independent Prostate Cancer (AIPC) Patients who Receive Sipuleucel-T Followed by Docetaxel Have Prolonged Survival (2007) (11)
- Life after failure of traditional androgen deprivation therapy. (2012) (11)
- Giant hydronephrosis of a duplex system associated with ureteral ectopia. (1989) (11)
- Glansectomy: an alternative surgical treatment for Buschke‐Lowenstein tumours of the penis (2001) (11)
- Application of a novel protein chip mass spectrometry technology for the identification of bladder cancer-associated biomarkers. (2003) (10)
- The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. (2010) (10)
- Immediate adjuvant intravesical chemotherapy after transurethral resection of bladder tumor. (1998) (10)
- Erattum: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial (Urology (September 1997) 50 (330-336)) (1998) (10)
- PROSTATIC TUMOR RELAPSE IN PATIENTS WITH SUPERFICIAL BLADDER TUMORS: 15-YEAR OUTCOME (1999) (10)
- Triple course external beam radiotherapy for carcinoma of the prostate. (1984) (10)
- Urethral carcinoma. (1983) (9)
- A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. (2005) (9)
- Comparison of countercurrent immunoelectrophoretic assay with commercial radioimmunoassay kits for measuring prostatic acid phosphatase. (1981) (9)
- Segmental testicular ischaemia mimicking testicular tumor. (1997) (9)
- Renal cell carcinoma with solitary metastases to pericardium. (1983) (9)
- Two-site monoclonal antibody-based immunoradiometric assay for measuring prostate secretory protein in serum. (1992) (9)
- Cancer serum index and prostatic acid phosphatase for detection of progressive prostatic cancer. (1985) (9)
- Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)—Phase III. (2012) (9)
- Cell-mediated immunity in patients with renal cell carcinoma as measured by leukocyte migration inhibition test. (1978) (8)
- Solitary lesions on bone scan in genitourinary malignancy. (1984) (8)
- Estimated potency of casodex: A problematic design [1] (multiple letters) (1997) (8)
- Experience with transureteroureterostomy in the paraplegic patient with irreversible vesicoureteral reflux. (1974) (8)
- Are monotherapy options reasonable for T3 prostate cancer? (1997) (8)
- Contemporary expectant therapy series: A viewpoint (1994) (8)
- Bone marrow and acid phosphatase by counterimmune electrophoresis: pre-treatment and post-treatment correlations. (1982) (8)
- Bicalutamide and Flutamide, Each in Combination with Luteinizing Hormone-Releasing Hormone Analogs, in Advanced Prostate Cancer: Exploratory Analysis of Impact of Extent of Disease by Bone Scan on Outcome (2000) (8)
- Feasibility of using guidelines to choose treatment for prostate cancer. (2010) (7)
- Well differentiated carcinoma of the prostate seeding a perineal needle biopsy tract. (1984) (7)
- Pyelocancerous backflow: a radiologic finding in renal malignancy. (1976) (7)
- Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer. (2020) (7)
- 19: Prospective Longitudinal Comparison of Health Related Quality of Life in Patients Undergoing Treatment for Localized Prostate Cancer: An Evaluation of Three Surgical Treatment Modalities from a Single Institution (2007) (7)
- Abstract of ASTRO scientific posters to be presented poster sessionSix-year experience with triple course irradiation for carcinoma of the prostate (1984) (7)
- Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial. (1997) (7)
- Primary mucinous adenocarcinoma of the renal pelvis. (1981) (6)
- Therapeutic strategies for local failure after radiation therapy for stage A-C carcinoma of the prostate (1993) (6)
- Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study. (1996) (6)
- Editorial: Improving outcomes for primary and salvage therapy of localized prostate cancer. (2003) (6)
- Gonadal steroids and body composition, strength, and sexual function in men. (2013) (6)
- Words of wisdom. Re: Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. (2009) (6)
- BCG treatment of superficial transitional cell carcinoma. (1991) (6)
- Oncodiagnosis panel: 1997. Prostatic carcinoma (1999) (6)
- Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-T trials in metastatic castration-resistant prostate cancer. (2010) (6)
- Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): Data from Southwest Oncology Group Trial 9346 (INT-0162). (2006) (6)
- Leukocyte migration inhibition assay in patients with bladder cancer. (1979) (6)
- A Urologist's Personal View of Prostate Cancer. (2016) (6)
- Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis. (2019) (6)
- Quality-of-life assessment in a randomized, double-blind study of sipuleucel-T in men with androgen-dependent prostate cancer. (2011) (6)
- The detection of prostate specific antigen, MHS-5, and other markers in invasive prostate cancer and seminal vesicle. (1992) (5)
- Overall survival (OS) benefit with sipuleucel-T by baseline PSA: An exploratory analysis from the phase III IMPACT trial. (2012) (5)
- Local results of external beam irradiation versus iodine-125 implantation for carcinoma of the prostate (1984) (5)
- Mortality in prostatic carcinoma (1989) (5)
- Drug Evaluation Oncologic, Endocrine & Metabolic: Bicalutamide (Casodex™) (1996) (5)
- Laparoscopic Radical Prostatectomy (2004) (5)
- Failure of anticytokeratin 18 antibody to improve flow cytometric detection of bladder cancer (1992) (5)
- Prostatic carcinoma with diffuse cutaneous metastases. (1978) (5)
- PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the antiandrogen casodex. (1995) (5)
- Primary mucus-secreting adenocarcinoma of the renal pelvis. (1979) (4)
- Timing of androgen deprivation therapy: some questions answered, others not. (2006) (4)
- Venous thromboembolism. (1989) (4)
- Contemporary management of prostate cancer with lethal potential. (2004) (4)
- Local failure and related complications after definitive treatment of clinical stage C carcinoma of the prostate by irradiation or surgery. (1990) (4)
- Serum PSA decline after Casodex withdrawal. (1994) (4)
- Radioimmunoassay versus counterimmune electrophoresis for measurement of serum prostatic acid phosphatase. (1982) (4)
- Editorial: A worldwide View of Bladder Cancer (1997) (4)
- What is the available evidence to support immediate adjuvant intravesical chemotherapy after transurethral resection of superficial transitional cell carcinoma of the bladder? (1998) (3)
- Leukocyte migration inhibition assay in patients with prostate adenocarcinoma (1981) (3)
- Renal failure associated with the use of thio-tepa. (1973) (3)
- Couch or crouch? Examining the prostate: a randomized study comparing the knee-elbow and the left-lateral position. (2001) (3)
- 674 INTEGRATED SAFETY RESULTS FROM FOUR RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF SIPULEUCEL-T (2010) (3)
- Scrotal skin recession phalloplasty. (1975) (3)
- Flow cytometric DNA analysis after immunoselection of bladder tumor cells with monoclonal antibody DU83.21 (1990) (3)
- Are three substages of clinical B prostate carcinoma useful in predicting disease-free survival? (1990) (3)
- 456 A randomized double-blind trial in 813 previously untreated metastatic prostate cancer (CaP) patients (PTS) comparing a new antiandrogen casodex® (bicalutamide) with eulexin (flutamide) in combination with luteinizing hormone releasing hormone analogue (LHRH-a) therapy (1995) (3)
- Genitourinary tumors, prostate (2012) (3)
- Editorial: Where Treatment May Be Necessary and Possible (1994) (3)
- Patient counseling regarding treatment of T1/2 (A/B) prostate cancer. A personal view. (1995) (2)
- Prostate-specific antigen after radiation therapy : Prognosis by pretreatment level and post-treatment nadir : Prostate-specific antigen: the best prostatic tumor marker (1997) (2)
- OUTCOME AFTER INTRAVESICAL BCG IS NOT AFFECTED BY T1a/T1b SUBSTAGING (1999) (2)
- PROSTATE CANCER SCREENING AT EASTERN VIRGINIA MEDICAL SCHOOL: AGE-ADJUSTED REFERENCE RANGES IN AFRICAN AMERICANS VERSUS CAUCASIANS (1999) (2)
- Separated pyelocolocutaneous diversion after bilateral ureterectomy and radical cystectomy for transitional cell carcinoma. (1997) (2)
- External sphincterotomy: rationale for the procedure and experiences with 150 patients (1975) (2)
- Large renal masses in young adults. (1986) (2)
- Practical system of assessment: an updated acronym for PSA. (2007) (2)
- Luteinizing hormone-releasing hormone monotherapy: a viable option for treatment of prostate cancer? (2001) (2)
- THERAPY FOR ADVANCED AND HORMONE REFRACTORY CANCER OF THE PROSTATE (2000) (2)
- Computer modeling technology to assess extracapsular tissue coverage of whole mount sections after retropubic and laparoscopic radical prostatectomy. (2007) (2)
- Quantification of extra-capsular prostate tissue from reconstructed tissue images (2004) (2)
- Collagen mass in prostatic bed after radical retropubic prostatectomy. (1997) (2)
- Summary of transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer (by Paul F. Schellhammer, MD, and Willet F. Whitmore, Jr, MD). 1976. (1997) (2)
- Metastatic castrate-resistant prostate cancer. (2015) (2)
- Prognostic value of poorly differentiated prostatic adenocarcinoma. (1983) (2)
- Clear cell carcinoma of the kidney simulating an intramural gastric tumour. (1971) (2)
- Pathological findings after preoperative irradiation for carcinoma of the urinary bladder. (1979) (2)
- I-125 interstitial implantation of the prostate. (1977) (2)
- Placement of double-pigtail ureteral stent via cystoscope. (1982) (2)
- [Comparative study of surgical efficacy in open versus laparoscopic prostatectomy: virtual prostate reconstruction and periprostatic tissue quantification]. (2007) (1)
- Treater to target: a urologist's personal experience with prostate cancer. (2012) (1)
- Witnessing the Transition of Open to Robotic Surgery (2011) (1)
- Prostate-specific Membrane Antigen Levels in Sera from Healthy Men and Patients with Benign Prostate Hyperplasia or Prostate Cancer 1 (1999) (1)
- Prostatectomy Evaluation using 3D Visualization and Quantitation (2005) (1)
- DNA Analyses of Bladder Tumor Cells Following Immunoselection with Anti-Bladder Tumor-Associated Monoclonal Antibodies (1987) (1)
- Editorial comment (2003) (1)
- Radical Retropubic Prostatectomy (2003) (1)
- Quality of Life: Impact of Prostate Cancer and its Treatment (2003) (1)
- Surgical Management of Squamous Cell Carcinoma of the Penis (2004) (1)
- 890: Multiple Fluorescence in Situ Hybridization (FISH) Probes Increase Sensitivity for Detection of Bladder Cancer (2006) (1)
- MP87-11 INTERIM ANALYSIS OF AN OPEN LABEL PHASE II STUDY OF ENZALUTAMIDE AND RADIUM RA 233 DICHLORIDE IN SYMPTOMATIC, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS. (2018) (1)
- Reply to P.C. Walsh (2009) (1)
- Fruit for thought. (1988) (1)
- Re: Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993. (2002) (1)
- ‘Should I get a PSA test?’ – the question is not that simple (2015) (1)
- Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer: will more prove better? (1998) (1)
- Radiation for Localized Prostatic Carcinoma (1995) (1)
- Treater to Target: Experiences of a Prostate Cancer Participant (2011) (1)
- Urological Survey: Abstracts: Principles of Oncology and Immunology, and Tumors of Bladder, Penis and UrethraAdditional Bacillus Calmette-Guerin Therapy for Recurrent Transitional Cell Carcinoma After an Initial Complete Response (1998) (1)
- Re: Prostatorectal fistula associated with 125iodine seed radiotherapy. (1984) (1)
- A worldwide view of bladder cancer. (1997) (1)
- Prospective, Longitudinal, Ongoing Study of Health Related Quality of Life (Qol) in Patients Undergoing Cryoablation as Compared to Brachytherapy for Localized Prostate Cancer (2008) (1)
- Electrosurgery. Principles, hazards, and precautions. (1974) (1)
- Monoclonal Antibody PD 41 Recognizes an Antigen Restricted to Prostate Adenocarcinomas 1 (2006) (1)
- Reflections on prostate cancer: personal experiences of two urologic oncologists (2008) (1)
- Ultrasound-guided brachytherapy: is it really better? (2000) (1)
- Testicular androgen ablation for prostate cancer. (1999) (1)
- A conversation between Darracott Vaughan and Paul Schellhammer (2008) (1)
- Disease-related effects of perioperative blood transfusions associated with 125I seed implantation for prostate carcinoma. (1990) (1)
- Mortality in prostatic carcinoma. (1986) (1)
- RE: A structured debate: immediate versus deferred androgen suppression in prostate cancer--evidence for deferred treatment. (2002) (1)
- Bicalutamide combination therapy versus castration alone: A combined analysis of historical data. (2004) (1)
- Intestinal strictures complicating preoperative radiation therapy followed by radical cystectomy. (1986) (1)
- Angiographic investigation of retroperitoneal space. (1978) (1)
- RESEARCH HIGHLIGHTS: EBM from the Cochrane Library (2009) (0)
- Re: Should the Urologist Treat Castration Resistant Prostate Cancer? Yes/No. (2016) (0)
- Immunoreactivity of monoclonal antibodies to human prostate and bladder tumor-associated antigens. Abstr. (1981) (0)
- Laparoscopic retroperitoneal lymphadenectomy - a routine therapeutic modality in the treatment of nonseminomatons testis cancer stage I (2002) (0)
- Monoclonal antibody turp 27 identifies a new prostate tumor marker (1985) (0)
- 693: Comparative Assessment of Open and Laparoscopic Prostatectomy by Computer Modeling Technology (2005) (0)
- Advances in Brief Quantitation of Serum Prostate-specific Membrane Antigen by a Novel Protein Biochip Immunoassay Discriminates Benign from Malignant Prostate Disease 1 (2001) (0)
- Testicular and Penile Cancer (2007) (0)
- Physicians can no longer ignore complementary medicine (2002) (0)
- Abstract D084: Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC)—final PROCEED analysis (2020) (0)
- Treatment principles for nonmuscle invasive bladder cancer (2008) (0)
- Sipuleucel-T (2019) (0)
- Comment on: Choices (2007) (0)
- Sipuleucel-T (2020) (0)
- Aggressive Urologic Malignancy in Heart Transplant Recipients (2010) (0)
- Comment on : A structured debate: Immediate versus deferred androgen suppression in prostate cancer: Evidence for deferred treatment (letter to the editor). Author's reply (2002) (0)
- Complex-negative Prostate Cancer Treatment Model of Major Histocompatibility Flt 3-Ligand Induces Transient Tumor Regression in an Ectopic Updated (2000) (0)
- Overall Survival Benefit with Sipuleucel-T by Baseline Prostate-Specific Antigen (PSA): An Exploratory Analysis from Three Phase 3 Trials (2012) (0)
- Surviving Prostate Cancer: What You Need to Know to Make Informed Decisions, E.F. Torrey, C. Stoiber. Yale University Press, New Haven, Connecticut (2006), 304 pages (2007) (0)
- Expectations of benefit in survival in patients choosing treatment for localized prostate cancer (2008) (0)
- A simplified stomal collecting device. (1973) (0)
- Advances in Brief Flt 3-Ligand Induces Transient Tumor Regression in an Ectopic Treatment Model of Major Histocompatibility Complex-negative Prostate Cancer 1 (2000) (0)
- Bladder Cancer (2021) (0)
- Mp14-02 Prospective Quality of Life Impact Analysis Following Localized Prostate Cancer Treatments: Brachytherapy, Cryotherapy, and Radical Prostatectomy Long-Term Follow-Up (2015) (0)
- Sexual Function After Permanent Prostate Brachytherapy Is Not Affected by Penile Bulb Dose (2005) (0)
- PROSPECTIVE LONGITUDINAL COMPARISON OF QUALITY OF LIFE OUTCOMES FOLLOWING TREATMENT OF LOCALIZED PROSTATE CANCER (2009) (0)
- Data shed light on salvage RT, immediate hormone Tx (2004) (0)
- Helping Patients Make Treatment Choices for Localized Prostate Cancer (2012) (0)
- Case series: organ sparing surgery in cancer of the penis and male/female urethra (1997) (0)
- Male external genitals reconstruction following tumor ablation (1992) (0)
- Testicular androgen ablation for prostate cancer [3] (multiple letters) (1999) (0)
- Immunohistochemical Localization of Prostate Carcinoma-associated Antigens1 (2006) (0)
- Contents Vol. 72, 2004 (2004) (0)
- Complications of Pelvic Lymphadenectomy and Interstitial Irradiation of A2 Tumors (1991) (0)
- Should we delay prostate radiotherapy? (1999) (0)
- 209: Prospective, Longitudinal, Comparitive Study of Health-Related Quality of Life (QOL) in Patients Undergoing Five Different Invasive Treatments for Localized Prostate Cancer: Update 2005 (2006) (0)
- Does Limited Pelvic Lymphadenectomy in Low-Risk Prostate Cancer Patients Affect Biochemical Recurrence? (2013) (0)
- Hyperplasia and Healthy Men ProstateAlgorithm Distinguishes Prostate Cancer from Benign Serum Protein Fingerprinting Coupled with a Pattern-matching Updated (2002) (0)
- First Annual Midwinter Meeting Society of Urologic Oncology (2001) (0)
- Monoclonal Antibodies to Human Prostate and Bladder Tumor-associated Antigens1 (2006) (0)
- Timing issues are important when treating invasive TCC (2003) (0)
- Legends in Urology. (2016) (0)
- The urologist in London. (1973) (0)
- PSA kinetics provide meaningful outcomes estimates (2005) (0)
- O Management of Patients with Bacilli Calmette-G & in-Refractory Carcinoma in Situ of the Urinary Bladder : Cost Implications of a Clinical Trial for Valruhicin (2005) (0)
- Intravesical chemotherapy with gamma linolenic acid becomes a reality. (1998) (0)
- Quality of life after definitive treatment for prostate cancer. Differences based on treatment modality (2000) (0)
- Panel IV: Locoregional disease (1992) (0)
- 1596: Choices for Definitive Treatment of Early-Stage Prostate Cancer: Results from the Compare Registry (2006) (0)
- Re: choices. M. I. Resnick J Urol 2006; 176: 2342. (2007) (0)
- Bladder cancer studies help pinpoint risk of recurrence (2004) (0)
- Editorial comment. (2011) (0)
- Re: Chemoprevention of prostate cancer. I. M. Thompson, C. M. Tangen, P. J. Goodman, M. S. Lucia and E. A. Klein. J Urol 2009; 182: 499-508. (2010) (0)
- Editorial Comment: Outcome for Surgically Staged Localized Prostate Cancer Treated With External Beam Radiation Therapy (1997) (0)
- Overview of contents. (1995) (0)
- Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry (2020) (0)
- Renal Cell Carcinoma in Children (1973) (0)
- Dietary data disappoint, but are not the final word (2006) (0)
- Subject Index Vol. 72, 2004 (2004) (0)
- Proteomics will yield precise therapeutic target (2004) (0)
- Penile and bladder cancer (1997) (0)
- Re: Prediction of erectile function following treatment for prostate cancer. (2012) (0)
- Reply by Author (2009) (0)
- 196: Prospective, Longitudinal, Comparative Study of Health Related Quality of Life in Patients Undergoing Invasive Treatments for Localized Prostate Cancer: Update 2004 (2005) (0)
- Re: Editorial comment on Laparoscopic radical prostatectomy: is intact organ removal attainable? Study of margin status. (2006) (0)
- Oestrogen redux: will transdermal delivery rebalance the risk–benefit equation? (2017) (0)
- Re: The role of radical cystectomy in the management of high grade superficial bladder cancer (Pa, P1, PIS and P2) (1991) (0)
- Radiotherapeutic Management of Prostate Adenocarcinoma (2000) (0)
- 2160 Strontium-89 and maximum androgen blockade: Reducing tumor burden in the bone in metastatic prostate cancer (1999) (0)
- 805: Prospective, Longitudinal, Comparative Study of Quality of Life in Patients Undergoing Invasive Treatments for Localized Prostate Cancer (2004) (0)
- Re: Chemoprevention of Prostate Cancer. Author's reply (2010) (0)
- THE PREDICTIVE RELIABILITY OF BIOCHEMICAL DISEASE FREE STATUS AT THE 3 YEAR FOLLOW-UP INTERVAL FOR CONTINUED BIOCHEMICAL DISEASE STATUS: RADIATION THERAPY VERSUS RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER (1999) (0)
- Reply by Petrylak. (2016) (0)
- Locoregional disease. (1992) (0)
- Prostatic carcinoma. (1999) (0)
- Clinical trials in prostate cancer. (2003) (0)
- Reply (2001) (0)
- Kidney neoplasms. (1979) (0)
- Morbidity of Local Failure After Definitive Treatment for Carcinoma of the Prostate (1987) (0)
- A history of the Society of Urologic Oncology. (2021) (0)
- Reply to P.H. Frankel et al (2009) (0)
- Legal implications of prostate cancer: what you should know. (1993) (0)
- Surgery or brachytherapy revisited. (1999) (0)
- Where treatment may be necessary and possible. (1994) (0)
- Testicular Carcinomas and Carcinoma of the Prostate (1978) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Paul F. Schellhammer?
Paul F. Schellhammer is affiliated with the following schools:
